ArticleSarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG2025
Survival in familial idiopathic pulmonary fibrosis and fibrotic hypersensitivity pneumonitis.
Article in Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFamilial pulmonary fibrosis (FPF) is defined as the occurrence of any interstitial lung disease (ILD) in two or more first- or second-degree relatives. Although the most frequently reported phenotype is idiopathic pulmonary fibrosis (IPF), other forms of ILD have been identified, such as fibrotic hypersensitivity pneumonitis (fHP). This study aims to explore survival between patients with IPF and fHP substratified by presence or absence of self-reported familial pulmonary fibrosis.
methodsFamily history was acquired systematically, and patients were stratified by IPF or fHP according to specific guidelines. Clinical data on pulmonary function and imaging were collected during the first follow-up evaluation of patients. All cases were reviewed in multidisciplinary meetings. Other ILD diagnosis was excluded.
resultsA total of 198 participants were included: 88 with IPF and 110 with fHP. In the IPF group, 36 had familial forms (F-IPF), and in the fHP group, 30 had familial fHP (F-fHP). The median follow-up time was 37 (3 - 1200) months. The variables age (hazard ratio [HR]: 1.03; 95% CI: 1.01 - 1.06; p = 0.01), FVC% (HR: 0.96; 95% CI: 0.94 - 0.98; p < 0.01), SpO2% (HR: 0.86; 95% CI: 0.76 - 0.97; p < 0.02), and family history of pulmonary fibrosis (HR: 1.79; 95% CI: 1.09 - 2.93; p = 0.02) were associated with mortality and were controlled before performing the survival curves. The median survival for the FPF group was 46 months compared to 75 months for the non-familial group (p = 0.009).
conclusionpatients with familial presentations of IPF and fHP have significantly lower survival compared to patients with non-familial presentations of the same diseases. In clinical practice across many countries, genetic testing is not widely available, so family history should always be investigated.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.